Payment overview · 2025
General Payments
$375.51
9 reported records · 5 companies
Healthcare provider profile · identity verified
Luis Daniel Ramos, MD
Allopathic & Osteopathic Physicians|General Practice · ORANGE CITY, FL · NPI 1447754825
Verified facts
What the public records show
CMS Open Payments records show Luis Daniel Ramos, MD received $375.51 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.73 | 40.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.47 | 40.3% | 3 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $35.70 | 9.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.76 | 5.5% | 1 | 2025 |
| ETS Wound Care LLC | Unresolved — no canonical attribution shown | $13.85 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $375.51 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $153.73 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $151.47 | 3 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $35.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| MIRRAGEN ADVANCED WOUND MATRIX Normalized: mirragen advanced wound matrix |
Device | ETS Wound Care LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
92 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 381 | 73 |
| Gabapentin | Gabapentin | 242 | 88 |
| Oxycodone Hcl | Oxycodone Hcl | 202 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 184 | 48 |
| Ibuprofen | Ibuprofen | 179 | 71 |
| Lidocaine | Lidocaine | 150 | 43 |
| Mounjaro | Tirzepatide | 144 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 140 | 47 |
| Lisinopril | Lisinopril | 137 | 62 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 123 | 40 |
| Ozempic | Semaglutide | 112 | 37 |
| Metformin Hcl | Metformin Hcl | 106 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 103 | 48 |
| Azithromycin | Azithromycin | 99 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 53 |
| Omeprazole | Omeprazole | 98 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 96 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 29 |
| Linzess | Linaclotide | 92 | 39 |
| Montelukast Sodium | Montelukast Sodium | 91 | 46 |
| Trazodone Hcl | Trazodone Hcl | 90 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 27 |
| Pregabalin | Pregabalin | 79 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 55 |
| Losartan Potassium | Losartan Potassium | 71 | 34 |
| Ondansetron Odt | Ondansetron | 70 | 22 |
| Baclofen | Baclofen | 67 | 28 |
| Methylprednisolone | Methylprednisolone | 67 | 61 |
| Meloxicam | Meloxicam | 65 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 25 |
| Simvastatin | Simvastatin | 58 | 35 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 57 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 31 |
| Famotidine | Famotidine | 54 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 44 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 30 |
| Prednisone | Prednisone | 49 | 33 |
| Tramadol Hcl | Tramadol Hcl | 48 | 24 |
| Clonidine Hcl | Clonidine Hcl | 47 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 20 |
| Carvedilol | Carvedilol | 43 | 23 |
| Trulicity | Dulaglutide | 43 | 13 |
| Eliquis | Apixaban | 41 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 15 |
| Farxiga | Dapagliflozin Propanediol | 39 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 14 |
| Furosemide | Furosemide | 36 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 35 | 21 |
| Buspirone Hcl | Buspirone Hcl | 34 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Glipizide | Glipizide | 33 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | 17 |
| Clonidine | Clonidine | 26 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 14 |
| Naproxen | Naproxen | 26 | 11 |
| Sertraline Hcl | Sertraline Hcl | 26 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 23 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | 11 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 12 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | 12 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 16 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 15 |
| Clonazepam | Clonazepam | 20 | 15 |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | 11 |
| Calcitriol | Calcitriol | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | 12 |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Ztlido | Lidocaine | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $375.51 · 9 records | ABBVIE INC. | AIRSUPRA, APLIGRAF, INCEPTIV, MIRRAGEN ADVANCED WOUND MATRIX, QULIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error